UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934







Date of Report: February  03, 2011

(Date of earliest event reported)




Theravance, Inc.

(Exact name of registrant as specified in its charter)





Delaware

(State or other jurisdiction 
of incorporation)


000-30319

(Commission File Number)


94-3265960

(IRS Employer 
Identification Number)






901 Gateway Boulevard, South San Francisco, CA

(Address of principal executive offices)

 

94080

(Zip Code)




650-808-6000
(Registrant's telephone number, including area code)




Not Applicable
(Former Name or Former Address, if changed since last report)








Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


 
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

  

 
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

  





Item 8.01. Other Events



On February 3, 2011, GlaxoSmithKline plc and Theravance, Inc. (the "Company") issued a press release announcing major milestones in two clinical development programs focused on new treatments for patients with chronic obstructive pulmonary disease (COPD). The first is the initiation of the Phase 3 program for the once-daily LAMA/LABA dual bronchodilator, GSK573719/vilanterol ('719/VI).  The second is the start of an extensive Phase 3b outcomes study to assess the potential for RELOVAIR(TM) to improve survival in those with COPD and a history of, or at risk from, cardiovascular disease.  A copy of the press release is filed as Exhibit 99.1 to this report and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits





(d) Exhibits

             99.1       Press Release of Theravance, Inc. dated February  03, 2011




SIGNATURE

      Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be
              signed on its behalf by the undersigned hereunto duly authorized.








Dated: February  03, 2011



THERAVANCE, INC.

By:  /s/ Michael W. Aguiar                      

     Michael W. Aguiar

     Chief Financial Officer 







Exhibit Index



Exhibit No.
Description


99.1
Press Release of Theravance, Inc. dated February  03, 2011